Radiosensitization of IDH-mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.

Sean Sachdev Crismita Dmello Adam M Sonabend

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Isocitrate dehydrogenase 1 mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy (RT) remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radio-resistance for IDH1m gliomas, and pharmacological targeting of this pathway may heighten RT-induced tumor response, providing a prospect of improved clinical outcomes.

Keyphrases

wild type
high grade
low grade
early stage
high glucose
radiation therapy
type diabetes
cancer therapy
adipose tissue
current status
drug delivery
skeletal muscle
smoking cessation